In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth

Division of Pfizer Inc.
www.wyeth.com

Latest From Wyeth

Aleve Challenge, New Study Catch Up To Advil 'Works Longer' Claim In NAD Review

Although 1993 studies to make Aleve available OTC didn't support claiming the naproxen oral analgesic lasted longer than ibuprofen-containing Advil, 2018 study Bayer submitted for National Advertising Division review shows Advil's efficacy doesn't exceed Aleve's. Report also says while Pfizer criticized inpatient methodology of Bayer's study, inpatient is industry standard method for pain medication trials.

OTC Drugs Ad Complaints

Pfizer Consumer Health True To Form Pending Move To JV With GSK

Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.

Consumer OTC Drugs

Pfizer Consumer Health True To Form Pending Move To JV With GSK

Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.

Commercial Consumer

Product Liability Returning To Supreme Court With Government, Former FDA Officials On Opposite Sides

US government supports Merck, saying FDA labeling decision preempts Fosamax failure-to-warn claim. Joshua Sharfstein and two other former FDAers argue Merck sought warning on a lesser injury.
Legal Issues Drug Safety
See All

Company Information

UsernamePublicRestriction

Register